Jul 19, 2023
Amar Sawhney is one of the most accomplished individuals in the realm of Medical Technology. His achievements and professional journey are unparalleled. In a conversation with Jasmeet, he recounts the path that led him to his current position. He imparts insight into effective leadership, emphasizing a life devoted to service and a keen focus on improving the healthcare system for patients. Keep a pen and paper handy to jot down his advice.
IN THIS EPISODE:
KEY TAKEAWAY:
RESOURCE LINKS:
GUEST BIOGRAPHY:
Dr. Amarpreet Sawhney is the CEO of Instylla, a company focused on embolic therapies for hypervascular tumors and control of hemorrhage, of Rejoni, a company developing products for preventing intrauterine scar formation; and of Pramand LLC, a company focused on developing biosurgery products. He was previously the Founder and CEO of Ocular Therapeutix, Augmenix, Confluent Surgical, and the technology founder of Focal and Access Closure. Amar’s innovations are the subject of over 120 issued and pending patents in biomaterials and bio-surgery. His inventions include several “first of a kind” surgical sealants, spacers, and drugs to be approved by the FDA, including ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for Lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Amar and his partner Fred Khosravi have created Incept LLC, which provides a platform to support other healthcare entrepreneurs.
YOUR HOST:
Jasmeet Sawhney is a life sciences industry executive, marketing leader, and serial entrepreneur with deep roots in technology and data analytics. He is currently the global head of marketing at Axtria. Jasmeet has over 20 years of experience in the life sciences domain and has helped build and scale three successful companies. He has received several company and individual awards, including Inc 500, Deloitte Fast 500, Crain’s NY Fast 50, NJBiz Fast 50, Business of the Year, SmartCEO Future 50, Top CMO, Forty Under 40, and many more.